MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team
MDxHealth SA announced that it has signed a lease agreement for a state-of-the-art laboratory and office facilities in Irvine, CA and has filed for CLIA certification of the US site. In addition, MDxHealth has filed for CLIA certification of its Liege facility.
The two-pronged commercialization strategy of the company is built on the development of companion diagnostics with top tier pharmaceutical companies, and on developing its own proprietary diagnostic, prognostic and predictive assays for a number of cancer indications to be commercialized through its CLIA laboratories. MDxHealth expects to launch its first assay for prostate cancer in 2012.
In conjunction with identifying a prime 13,448 square foot location in Irvine, MDxHealth has hired Miriam Reyes, as Senior Director Laboratory Operations, and Beth Davis as Senior Director Managed Care. Both bring extensive experience in molecular cancer diagnostics to MDxHealth. MDxHealth is building a world class scientific and commercial team for its US operations and plans further expansion in the months ahead. In September 2010, the company already announced the appointments of Dr. Melissa A. Thompson as Vice President Regulatory Affairs and Quality Assurance, and of Christopher Thibodeau as Vice President Commercial Operations.
"Establishing a US infrastructure that includes CLIA certification will allow us to penetrate the US market more efficiently and is key to our long-term business strategy," said Dr. Jan Groen, CEO of MDxHealth. "Irvine is a hotbed for the healthcare industry and an excellent location for our company to attract the best and brightest talent, and our site is large enough to accommodate our growth over the next few years. I am also very pleased that we were able to attract two highly experienced industry professionals to manage laboratory operations and reimbursement."
Other news from the department business & finance
